About Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist used in metabolic research. Supplied as a lyophilized powder for laboratory studies investigating dual incretin receptor activation, insulin-related signaling pathways, and glucose homeostasis mechanisms in controlled experimental models. Each batch undergoes analytical verification for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: >95-99 (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort.
Recent research on Tirzepatide: Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort.
Read Full Study on PubMedIncretin Therapy Before Metabolic and Bariatric Surgery: Cardiorenal Protection or Physiological Preconditioning?
Recent research on Tirzepatide: Incretin Therapy Before Metabolic and Bariatric Surgery: Cardiorenal Protection or Physiological Preconditioning?
Read Full Study on PubMedAdditional Studies
Recurrent In-Stent Restenosis and Accelerated Neoatherosclerosis in a Middle-Aged Woman With High Inflammatory Burden.
Recent research on Tirzepatide: Recurrent In-Stent Restenosis and Accelerated Neoatherosclerosis in a Middle-Aged Woman With High Inflammatory Burden.
Read on PubMedReal-world, digital-first delivery of GLP-1 receptor agonist therapy in women.
Recent research on Tirzepatide: Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women.
Read on PubMedGlucagon-Like Peptide-1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity.
Recent research on Tirzepatide: Glucagon-Like Peptide-1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity.
Read on PubMedWeight Management in Obesity-Associated Sleep-Disordered Breathing: Mechanisms, Clinical Management, and Emerging Therapies.
Recent research on Tirzepatide: Weight Management in Obesity-Associated Sleep-Disordered Breathing: Mechanisms, Clinical Management, and Emerging Therapies.
Read on PubMedTirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study.
Recent research on Tirzepatide: Tirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study.
Read on PubMedTirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling.
Recent research on Tirzepatide: Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling.
Read on PubMedRelated Research
Purchase Tirzepatide from Origin Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.